VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ADGM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ADGMAdagio Medical Holdings, Inc.
$0.65$10M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksADGMBalance Sheet

Adagio Medical Holdings, Inc. (ADGM) Balance Sheet

5Y historyFree accessUpdated daily

Financial leverage has intensified significantly, with the debt-to-equity ratio climbing to 4.21 in 2026Q1 from 1.75 in 2025Q4, indicating a deteriorating capital structure.

ADGM Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21
Total Current Assets15.86M20.08M25.35M5.18M6.73M19.72M
Cash & Short-Term Investments12.91M17.11M20.59M1.38M5.55M18.85M
Cash Only12.91M17.11M20.59M1.38M5.55M18.85M
Short-Term Investments000000
Accounts Receivable0035K71K033K
Days Sales Outstanding--47.4986.38-44.61
Inventory1.6M1.67M2.57M3.32M367K334K
Days Inventory Outstanding1.41K892.22483.53928.43153.09105.28
Other Current Assets1.34M1.3M222K177K527K241K
Total Non-Current Assets23.45M23.17M23.1M1.64M1.97M1.72M
Property, Plant & Equipment2.52M2.23M2.15M1.62M1.94M1.7M
Fixed Asset Turnover0.00x-0.13x0.19x0.10x0.16x
Goodwill13.97M13.97M13.97M000
Intangible Assets6.97M6.97M6.97M000
Long-Term Investments000000
Other Non-Current Assets1K3K14K23K26K22K
Total Assets39.31M43.25M48.45M6.83M8.7M21.44M
Asset Turnover0.00x-0.01x0.04x0.02x0.01x
Asset Growth %258.41%-10.72%609.86%-21.52%-59.44%-
Total Current Liabilities8.57M8.23M7.76M47.18M12.97M2.59M
Accounts Payable1.22M1.08M2.84M3.83M1.01M578K
Days Payables Outstanding981.94577.38535.161.07K421.73182.18
Short-Term Debt225K155K143K38.13M9.5M0
Deferred Revenue (Current)000000
Other Current Liabilities7.13M7M2.16M1.64M0843K
Current Ratio1.85x2.44x3.27x0.11x0.52x7.62x
Quick Ratio1.66x2.24x2.93x0.04x0.49x7.49x
Cash Conversion Cycle429.15--4.14-55.59--32.3
Total Non-Current Liabilities25.01M22.62M20.77M91.67M91.61M91.47M
Long-Term Debt23.86M21.6M16.08M143K00
Capital Lease Obligations629K046K52K134K0
Deferred Tax Liabilities3.53M883K883K000
Other Non-Current Liabilities263K132K3.77M91.48M91.47M91.47M
Total Liabilities33.58M30.85M28.54M138.85M104.57M94.06M
Total Debt24.09M21.76M16.27M38.4M9.8M0
Net Debt11.18M4.65M-4.32M37.02M4.25M-18.85M
Debt / Equity4.21x1.75x0.82x---
Debt / EBITDA-1.29x-----
Net Debt / EBITDA-0.60x-----
Interest Coverage-7.56x-7.63x-49.79x-16.84x-171.80x-
Total Equity5.72M12.4M19.91M-132.02M-95.88M-72.62M
Equity Growth %-77.98%-37.72%115.08%-37.7%-32.03%-
Book Value per Share0.260.751.31-16.81-5.00-3.78
Total Shareholders' Equity5.72M12.4M19.91M-132.02M-95.88M-72.62M
Common Stock2K2K2K1K1K1K
Retained Earnings-102.63M-95.61M-70.59M-133.65M-97.06M-73.39M
Treasury Stock000000
Accumulated OCI-143K-99K1K17K28K4K
Minority Interest000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Capital Runway and Dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Eroding Equity and Asset Base

As reported in recent financial filings, ADGM's total assets have contracted from $107.2 million in 2024Q3 to $39.3 million in 2026Q1, reflecting a significant reduction in the company's resource base as it continues to fund developmental activities without offsetting revenue generation.

The sharp decline in total assets, coupled with the persistent accumulation of a $102.6 million deficit in retained earnings, suggests a business model that is rapidly consuming its capital foundation. This trajectory indicates that the company is struggling to maintain its operational scale, which may necessitate further external financing to prevent a total depletion of equity.

Leverage Rising Amidst Capital Scarcity

Based on the latest quarterly data, ADGM's debt-to-equity ratio has climbed to 4.21 in 2026Q1, a marked increase from 1.75 in 2025Q4, indicating that the company is increasingly relying on debt obligations to sustain its operations as equity buffers continue to thin.

The rise in leverage appears to be a necessity-driven response to the lack of internal cash generation rather than a strategic capital allocation choice. Investors should monitor this trend closely, as the mounting debt burden in a pre-revenue environment increases the risk of insolvency or highly dilutive restructuring events.

Diminishing Cash Runway and Liquidity

According to the company's balance sheet, cash and equivalents have dwindled to $12.9 million as of 2026Q1, down from $28.3 million in 2024Q3, which suggests a tightening liquidity position that limits the firm's ability to absorb unexpected clinical or regulatory setbacks.

While the current ratio of 1.85 provides a superficial appearance of stability, the underlying cash burn rate relative to the remaining balance indicates a limited window for operational survival. The company's liquidity buffer appears insufficient to support long-term R&D cycles without a near-term capital infusion.

Goodwill Impairment and Asset Quality

As indicated by the financial statements, the presence of $14.0 million in goodwill on the balance sheet warrants further investigation, as it represents a significant portion of total assets for a firm that has yet to demonstrate commercial viability or positive cash flow.

The persistence of this goodwill figure, despite the company's ongoing operating losses and lack of revenue, may suggest that the carrying value of these intangible assets is at risk of impairment. If the company fails to reach commercial milestones, these assets could be written down, further eroding the already fragile equity position.

ADGM — Frequently Asked Questions

Quick answers to the most common questions about buying ADGM stock.

What are the total assets of Adagio Medical Holdings, Inc. (ADGM)?

As of 2025, Adagio Medical Holdings, Inc. (ADGM) had total assets of $43.3M including $20.1M in current assets.

How much debt does Adagio Medical Holdings, Inc. (ADGM) have?

Adagio Medical Holdings, Inc. (ADGM) carries total debt of $21.8M, offset by $17.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Adagio Medical Holdings, Inc.?

Adagio Medical Holdings, Inc. (ADGM) has total shareholders' equity (book value) of $12.4M ($0.75 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Adagio Medical Holdings, Inc.'s current ratio and liquidity?

Adagio Medical Holdings, Inc. (ADGM) reported a current ratio of 2.44x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.